Oragenics, Inc. (OGEN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Oragenics, Inc. (OGEN) closed at USD 0.44 on 2026-10-14, a change of -66.2 % over the past year, with a market capitalization of USD 1.97M.

Oragenics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Oragenics, Inc. key figures

Previous close

USD 0.44 (2026-10-14)

1-year change

-66.2 %

Market cap

USD 1.97M

Enterprise value

USD -1.9M

P/E ratio (trailing)

-0.18

P/E ratio (forward)

-0.04

EPS (trailing)

-2.38

EPS (forward)

-10.80

PEG ratio

-8.96

Price to book

0.54

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

26.79

Employees

3

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Oragenics, Inc.

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Oragenics, Inc. and compare it with other stocks.